The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharmaceuticals Share News (FARN)

Share Price Information for Faron Pharmaceuticals (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 96.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 4.00 (4.167%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 96.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: 4Global wins deal; James Cropper profit warning

Mon, 31st Oct 2022 19:58

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

4Global PLC - London-based data, services and software for sporting events and the promotion of physical activity - Secures a GBP4 million contract over five years with an unnamed "major sporting infrastructure project" for an unspecified city in the Middle East. "Approximately GBP600,000 of the project is expected to be delivered and recognised in the current financial year and the project includes an opportunity for additional scope throughout the engagement," it says.

----------

James Cropper PLC - paper products manufacturer based in Cumbria, England - Says achieves break-even position in half-year to September 24. Revenue rises 26% year-on-year, though rising costs put pressure on bottom-line. Says energy costs have more than doubled. "The impact of inflationary pressures had been mitigated in the first part of the year by the application of energy surcharges but energy prices again spiked from late July and again in August. At the same time raw materials (which represent a larger proportion of overall costs) have been subject to unprecedented inflationary headwinds, rising 20% over the same period," James Cropper says. Adds: "The second half of the year shows a recovery through aggressive pricing actions and surcharges, supported by the recently announced government support on energy prices. Each division is projecting volume growth over the second half. Order books are full and the company is focused on a range of enabling actions to build a solid foundation for continued future growth." Company cuts annual outlook, however. Now expects full-year adjusted pretax profit of GBP2.0 million, versus previous market expectations of GBP5.4 million.

----------

Ncondezi Energy Ltd - power development company - Says feasibility study for battery energy storage system project confirms it is "technically viable and attractive". Study notes potential for 20% to 30% capital expenditure savings. Also says project can deliver first power of up to 60 megawatts within 18 months of financial close, with full 300 megawatts over 28 months. Ncondezi says has extended capital runway to November. Says it needs and intends to secure additional funding before the end of November, with "various options available and under consideration". This includes the potential additional tranche of GBP150,000 that may be available to it under the terms of the convertible loan facility it announced back in mid-September.

----------

Vast Resources PLC - London-based miner with projects in Romania and Zimbabwe - Revenue in 12 months ended April 30 surges to USD3.8 million from USD896.000. Pretax loss, however, widens to USD15.5 million from USD7.7 million. Posts exchange loss of GBP3.8 million, compared to GBP2.6 million gain a year earlier. In addition, vast says it has raised GBP1.5 million in placing of 652.0 million shares at 0.225 pence each. Vast adds: "The net cash raised from the placing will ensure sufficient levels of working capital are maintained to meet the company’s corporate obligations as well as cover certain transaction costs linked to possible new opportunities the company is investigating."

----------

Rockhopper Exploration PLC - Salisbury, England-based oil & gas exploration and production company - Updates on arbitration of dispute with Italian government. On Friday, Italy submitted an application to the International Centre for Settlement of Investment Disputes seeking to annul a recent award to Rockhopper, and requested a provisional stay of the enforcement of the EUR190 million award. Chief Executive Officer Samuel Moody calls the news "disappointing", adding: "Based on legal advice we believe annulment proceedings are likely to take approximately 18 to 24 months, albeit interest will commence accruing again in December 2022. We remain confident in the strength of our case, as was reflected in the unanimous decision underpinning the Award in August, and very much hope and believe the annulment request will be rejected in due course." Rockhopper says it has a non-binding offer in place for funding to fight the annulment and enforce the award.

----------

Alba Mineral Resources PLC - explorer with assets in Greenland, Ireland and the UK - Submits to watchdog an updated permit application to dewater the Llechfraith Shaft. In November 2021, the Natural Resources Wales regulator refused to grant Alba an application to dewater the Llechfraith Shaft. Since then, Alba has submitted to NRW additional data and analysis.

----------

R&Q Insurance Holdings Ltd - Bermuda-based specialty non-life insurer formerly known as Randall & Quilter Investment - Says gross written premiums in Program Management business up 83% to USD1.3 billion in nine months ended September 30, from USD714 million a year earlier. Programme fee income doubles to USD60 million.

----------

Blue Star Capital PLC - Sussex-based investment company focused on e-sports, payments and technology - Investee Dynasty Gaming & Media Pte Ltd signs distribution agreement with Indosat Ooredoo Hutchison, a telecommunications company, with about "100 million subscribers in Indonesia". Dynasty to offer play-to-earn games, developed by Pioneer Media Holdings Inc, to IOH. Pioneer and Dynasty have a game publishing agreement. Deal allows Dynasty to exclusive license to publish, market, promote and distribute Pioneer games in southeast Asia, India, and Australia.

----------

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical-stage biopharmaceutical company - Moves to second level of Phase I/II BEXMAB study, which is probing bexmarilimab in tandem with standard of care to treat hematological malignancies. Hematological malignancies are blood cancers. Faron says: "All first-stage cohort patients are alive. The longest treated patient at three cycles has revealed partial response as observed by reduced cancer activity with reduced blast (cancer cell) counts and normalised blood cell counts. Initial data from patients dosed with bexmarilimab also show a significant reduction in levels of soluble Clever-1 protein in the blood of treated patients." Dose will now be escalated.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
13 Sep 2018 08:36

Faron losses widen following disappointing Traumakine trial

(Sharecast News) - Faron Pharmaceuticals' operating loss doubled in the first half of its trading year following the group's disappointing trial on its Traumakine treatment.

Read more
12 Sep 2018 13:48

Faron Pharmaceuticals Says New Clever-1 Data Shows B Cell Response

LONDON (Alliance News) - Faron Pharmaceuticals Ltd said Wednesday that new data from its cell surface receptor Clever-1 showed B cell response control and humoral antibody production.The by

Read more
6 Sep 2018 16:01

UK Earnings, Trading Statements Calendar - Next 7 Days

Friday 7 September Secure Income REITHalf Year Results Ashmore GroupFull Year Year

Read more
21 Jun 2018 16:31

DIRECTOR DEALINGS: Faron Pharmaceuticals Directors Buy Shares

LONDON (Alliance News) - Faron Pharmaceuticals Oy said on Thursday several directors purchased shares over the course of three days from Tuesday to Thursday.On Tuesday, Non-Executive Matti

Read more
14 Jun 2018 11:30

Faron Pharmaceutics Reports Inconsistent Traumakine Biomarker Results

LONDON (Alliance News) - Faron Pharmaceuticals Oy on Thursday said preliminary biomarker data from its Traumakine phase III trial has produced inconsistent results.Faron is testing in a III

Read more
14 Jun 2018 11:00

WINNERS & LOSERS SUMMARY: Rolls Royce Flies High With Planned Job Cuts

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.----------FTSE 100 - up 2.6%. The jet engine maker said it will cut

Read more
24 May 2018 16:10

UK Shareholder Meetings Calendar - Next 7 Days

Friday 25 MayHochschild MiningFerrexpoKeywords Mutual (re managed 28 events 29 Stobart Life (re of

Read more
11 May 2018 08:45

Faron Says Traumakine Trial Did Not Produce Expected Results

LONDON (Alliance News) - Faron Pharmaceuticals Ltd said Friday that initial review of the Phase III trial for Traumakine drug used for the treatment of lung inflammation did not produce the seen a

Read more
8 May 2018 11:10

WINNERS & LOSERS SUMMARY: Virgin Money Gains On CYBG Takeover Offer

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Tuesday.----------FTSE 100 - up 4.1%. The Irish drugmaker said it has agreed

Read more
8 May 2018 10:17

Faron Pharmaceuticals Shares Dive As Traumakine Fails In Latest Test

LONDON (Alliance News) - Shares in Finnish firm Faron Pharmaceuticals Oy plunged on Tuesday as the company reported "extremely disappointing" results from its flagship Traumakine shares

Read more
8 May 2018 07:01

LONDON MARKET EARLY CALL: Stocks Called Lower As Iran Fears Boost Oil

LONDON (Alliance News) - Stock prices in London are seen opening lower on Tuesday following Monday's UK bank holiday as Chinese exports recovered at a faster pace in April amid concerns the US

Read more
1 May 2018 16:15

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 2 May Direct Line Insurance GroupQ1 ResultsConvaTec GroupQ1 GroupHalf

Read more
4 Apr 2018 12:53

Tiziana Appoints Leopoldo Zambeletti As Non-Executive Director

LONDON (Alliance News) - Tiziana Life Sciences PLC, a biotechnology company developing drugs for cancer and autoimmune diseases, said Wednesday Leopoldo Zambeletti has joined

Read more
9 Feb 2017 08:20

Faron Pharmaceuticals makes solid progress with drug programmes

(ShareCast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals updated the market on Thursday, ahead of its full year 2016 audited financial results which its board said will be announced on 29 March. The AIM-traded firm said for its Traumakine project, it expects to obtain the re

Read more
31 Oct 2016 12:44

Faron Pharma granted protection for IFN-beta by Finnish patent office

(ShareCast News) - Faron Pharmaceuticals' patent application to protect the intravenous use of interferon-beta, a cytokine protein, in a novel formulation has been accepted by the Finnish patent office that enables the company to build a global proprietary position for its Traumakine drug. The claim

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.